Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 5571 · Biosimilars Access and Affordability Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1320f–1 Selection of negotiation-eligible drugs as selected drugs

+81 −8729 of 33 shown
More for 42 U.S.C. § 1320f–1
Read § 1320f–1Only this section
33 changes the bill asks for here, 29 carried out
  1. Carried out:

    in paragraph (1), in the matter preceding subparagraph (A), by striking such year and each subsequent year beginning before the first year that begins at least 9 months and inserting the year of the selected drug publication date for such initial price applicability year and each subsequent year, except that a drug or biological product shall no longer be a selected drug beginning on the first day of the year that begins; and

  2. Carried out:

    in subparagraph (B), by striking or during the negotiation period with respect to such initial price applicability year and inserting the first day of such initial price applicability year; and

  3. Not carried out:

    in the flush text following subparagraph (B)—

    We can't read how this instruction is worded yet, so it isn't shown in the text.

    Technical detailno-pattern: in the flush text following subparagraph (X) —
  4. Carried out:

    by striking and shall continue to and inserting if such negotiation period has not yet ended, shall not have its maximum fair price or the explanation of such maximum fair price published under section 1195(a) if such publication has not yet occurred, and shall;

  5. Carried out:

    by inserting solely before with respect to the number; and

  6. Carried out:

    by inserting , but no maximum fair price shall apply for such initial price applicability year in accordance with paragraph (1) before the period at the end;

  7. Not carried out:

    in subparagraph (A), by striking an extended monopoly drug (as defined in section 1194(c)(4);

    “an extended monopoly drug (as defined in section 1194(c)(4)” isn't in § 1320f–1(f)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“an extended monopoly drug (as defined in section 1194(c)(4)” not found in /us/usc/t42/s1320f–1/f/1/A
  8. Carried out:

    in the heading, by striking Request required and inserting Procedures;

  9. Carried out:

    by redesignating clauses (i) and (ii) as clauses (ii) and (iii) respectively;

  10. Carried out:

    by inserting before clause (ii) (as so redesignated) the following:(i) Automatic delay.— (I) In general.— The Secretary shall apply, with respect to a biological product described in subparagraph (A), the rules described in subparagraph (A) of paragraph (2) (subject to subparagraphs (B) and (C) of such paragraph) if, prior to the selected drug …

  11. Carried out:

    by striking subclause (II);

  12. Not carried out:

    by striking In general and all that follows through unless and inserting Delay upon request.— The Secretary shall provide for a delay under paragraph (2)(A) if; and

    “In general” isn't in § 1320f–1(f)(1)(B)(ii) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“In general” not found in /us/usc/t42/s1320f–1/f/1/B/ii
  13. Not carried out:

    by striking subparagraph (2)(A) or; and inserting paragraph (2)(A), provided that a determination of high likelihood is made under paragraph (3).; and

    “subparagraph (2)(A) or;” isn't in § 1320f–1(f)(1)(B)(ii) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“subparagraph (2)(A) or;” not found in /us/usc/t42/s1320f–1/f/1/B/ii
  14. Carried out:

    in the heading, by inserting for a delay upon request after documents;

  15. Carried out:

    in subclause (I), in the matter before item (aa), by striking clause (i) and inserting clause (ii);

  16. Carried out:

    in subclause (I)(bb), by inserting to the extent available, before all agreements; and

  17. Carried out:

    by inserting the anticipated launch date before capital investment; and

  18. Carried out:

    by striking year (or the 2 years, as applicable) and inserting applicable period; and

  19. Carried out:

    in subparagraph (C)(i), by striking paragraph (2)(D)(iv) and inserting paragraph (2)(C)(iii);

  20. Carried out:

    in the heading, by striking 1 year and inserting 2 years;

  21. Carried out:

    by inserting or paragraph (1)(B)(i) applies after under paragraph (3); and

  22. Carried out:

    by striking 1 year and inserting 2 years;

  23. Carried out:

    by striking subparagraph (B) and inserting the following:(B) If not licensed and marketed during the delay.— If, during the time period between the selected drug publication date on which the biological product would have been included on the list as a selected drug pursuant to subsection (a) but for subparagraph (A), and the selected …

  24. Carried out:

    by striking subparagraph (C);

  25. Carried out:

    by redesignating subparagraph (D) as subparagraph (C); and

  26. Carried out:

    by striking clauses (ii) and (iii);

  27. Carried out:

    by redesignating clause (iv) as clause (ii); and

  28. Carried out:

    in clause (ii)(II) (as so redesignated), by striking paragraph (1)(B)(ii)(I)(bb) and inserting paragraph (1)(B)(iii)(I)(bb);

  29. Carried out:

    by striking paragraph (3) and inserting the following:(3) High likelihood.— (A) In general.— Subject to subparagraph (B), for purposes of this subsection, there is a high likelihood described in paragraph (1) or paragraph (2), as applicable, if the Secretary determines that information submitted to the Secretary by any person or …

  30. Carried out:

    in subparagraph (A), by striking subparagraphs (B)(ii)(II) and (C)(ii) of paragraph (2) and inserting paragraph (2)(B)(ii); and

  31. Carried out:

    in clause (i), by striking subclause (I) and inserting the following:(I) 75 percent of the amount by which the average manufacturer price, as reported by the manufacturer of such covered part D drug under section 1927 (or, if not reported by such manufacturer under section 1927, as reported by such manufacturer to the Secretary pursuant to the …

  32. Carried out:

    in clause (ii), by striking subclause (I) and inserting the following:(I) 80 percent of the amount by which the payment amount for such biological product under section 1847A(b), with respect to each of the calendar quarters of the price applicability period that would have applied but for this subsection; exceeds— (aa) for the initial price …

  33. Carried out:

    by adding at the end the following new subsection:(g) Definition of marketed.— In this section, the term “marketed” means, with respect to a drug or biological product (including a biosimilar biological product) introduced or delivered for introduction into interstate commerce..

§ 1320f–1(b)–(c)

Start of § 1320f–1 to (b)(2) unchanged ·

(3) Inclusion of delayed biological products Pursuant to subparagraphs (B)(ii)(I) and (C)(i) of subsection (f)(2), the Secretary shall select and include on the list published under subsection (a) the biological products described in such subparagraphs. Such biological products shall count towards the required number of drugs to be selected under subsection (a)(1).

(c) Selected drug

(1) In general For purposes of this part, in accordance with subsection (e)(2) and subject to paragraph (2), each negotiation-eligible drug included on the list published under subsection (a) with respect to an initial price applicability year shall be referred to as a “selected drug” with respect to [inserted: the year of the selected drug publication date for ]such [inserted: initial price applicability ]year and each subsequent year[inserted: ,] [inserted: except that a drug or biological product shall no longer be a selected drug ]beginning [struck: before][inserted: on] the first [inserted: day of the ]year that begins [struck: at least 9 months ]after the date on which the Secretary determines at least one drug or biological product—

(A) is approved or licensed (as applicable)—

(i) under section 355(j) of title 21 using such drug as the listed drug; or

§ 1320f–1(c)–(d)

(c)(1)(A)(ii)–(2) unchanged ·

(A) that is included on the list published under subsection (a) with respect to an initial price applicability year; and

(B) for which the Secretary makes a determination described in paragraph (1) before [struck: or during ]the [struck: negotiation][inserted: first] [struck: period][inserted: day] [struck: with][inserted: of] [struck: respect to ]such initial price applicability year;

shall not be subject to the negotiation process under section 1320f–3 of this title with respect to such negotiation period [struck: and][inserted: if] [inserted: such negotiation period has not yet ended, ]shall [struck: continue][inserted: not] [struck: to][inserted: have] [inserted: its maximum fair price or the explanation of such maximum fair price published under section 1195(a) if such publication has not yet occurred, and shall ]be considered a selected drug under this part [inserted: solely ]with respect to the number of negotiation-eligible drugs published on the list under subsection (a) with respect to such initial price applicability year[inserted: , but no maximum fair price shall apply for such initial price applicability year in accordance with paragraph (1)].

(d) Negotiation-eligible drug

(1) In general For purposes of this part, subject to paragraph (2), the term “negotiation-eligible drug” means, with respect to the selected drug publication date with respect to an initial price applicability year, a qualifying single source drug, as defined in subsection (e), that is described in either of the following subparagraphs (or, with respect to the initial price applicability year 2026 or 2027, that is described in subparagraph (A)):

§ 1320f–1(f)Special rule to delay selection and negotiation of biologics for biosimilar market entry(1)–(4)

(d)(1)(A)–(f) unchanged ·

(1) Application

(A) In general Subject to subparagraph (B), in the case of a biological product that would (but for this subsection) be an extended-monopoly drug (as defined in section 1320f–3(c)(4) of this title) included as a selected drug on the list published under subsection (a) with respect to an initial price applicability year, the rules described in paragraph (2) shall apply if the Secretary determines that there is a high likelihood (as described in paragraph (3)) that a biosimilar biological product (for which such biological product will be the reference product) will be licensed and marketed under section 262(k) of this title before the date that is 2 years after the selected drug publication date with respect to such initial price applicability year.

(B) [struck: Request required][inserted: Procedures]

(i) [inserted: Automatic delay.—]

(I) [inserted: In general.—] [inserted: The Secretary shall apply, with respect to a biological product described in subparagraph (A), the rules described in subparagraph (A) of paragraph (2) (subject to subparagraphs (B) and (C) of such paragraph) if, prior to the selected drug publication date for the list published under subsection (a) with respect to the initial price applicability year for which the biological product may have been included as a selected drug on such list but for paragraph (2)(A)—]

(aa) [inserted: the manufacturer of a biosimilar biological product for which such biological product will be the reference product has publicly disclosed in a press release or other communication, or the Secretary determines from information from any other source—]

(AA) [inserted: that such manufacturer’s application for licensure under section 351(k) of the Public Health Service Act for the biosimilar biological product was accepted for review or approved by the Food and Drug Administration; or]

(BB) [inserted: that such manufacturer’s clinical study or studies of the biosimilar biological product as described in section 351(k)(2)(A)(i)(I)(cc) of the Public Health Service Act were initiated and remain ongoing, are complete, or that no such study or studies are necessary; and]

(bb) [inserted: subject to subclause (II), based on information submitted to the Secretary by any person or obtained by the Secretary from any other source, the Secretary determines that the manufacturer of the biosimilar biological product expects that such product will be marketed before the date that is 2 years after the selected drug publication date with respect to such initial price applicability year.]

(II) [inserted: Requirements.—]

(aa) [inserted: In general.—] [inserted: Before making the determination described in subclause (II)(bb), the Secretary shall—]

(AA) [inserted: inform the manufacturer of the biosimilar biological product of the information on which the Secretary intends to rely in making such determination; and]

(BB) [inserted: require that such manufacturer confirms in writing, under penalty of perjury, the accuracy of such information or corrects any such inaccurate information, including its expected marketing date.]

(bb) [inserted: Clarification.—] [inserted: The existence of pending or prospective patent litigation over a biosimilar biological product shall not preclude application of the rules described in subparagraph (A) of paragraph (2) (subject to paragraphs (B) and (C) of such paragraph).]

[struck: (i)] [inserted: (ii)] In general The Secretary shall not provide for a delay under—

(I) paragraph (2)(A) unless a request is made for such a delay by a manufacturer of a biosimilar biological product prior to the selected drug publication date for the list published under subsection (a) with respect to the initial price applicability year for which the biological product may have been included as a selected drug on such list but for subparagraph (2)(A); or

[struck: (II)] [struck: paragraph (2)(B)(iii) unless a request is made for such a delay by such a manufacturer prior to the selected drug publication date for the list published under subsection (a) with respect to the initial price applicability year that is 1 year after the initial price applicability year for which the biological product described in subsection (a) would have been included as a selected drug on such list but for paragraph (2)(A).]

[struck: (ii)] [inserted: (iii)] Information and documents[inserted: for a delay upon request]

(I) In general A request made under clause ([struck: i][inserted: ii]) shall be submitted to the Secretary by such manufacturer at a time and in a form and manner specified by the Secretary, and contain—

(aa) information and documents necessary for the Secretary to make determinations under this subsection, as specified by the Secretary and including, to the extent available, items described in subclause (III); and

(bb) [inserted: to the extent available, ]all agreements related to the biosimilar biological product filed with the Federal Trade Commission or the Assistant Attorney General pursuant to subsections (a) and (c) of section 1112 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

(II) Additional information and documents After the Secretary has reviewed the request and materials submitted under subclause (I), the manufacturer shall submit any additional information and documents requested by the Secretary necessary to make determinations under this subsection.

(III) Items described The items described in this clause are the following:

(aa) The manufacturing schedule for such biosimilar biological product submitted to the Food and Drug Administration during its review of the application under such section 262(k) of this title.

(bb) Disclosures (in filings by the manufacturer of such biosimilar biological product with the Securities and Exchange Commission required under section 78l(b), 78l(g), 78m(a), or 78o(d) of title 15 about [inserted: the anticipated launch date ]capital investment, revenue expectations, and actions taken by the manufacturer that are typical of the normal course of business in the [struck: year (or the 2 years, as ]applicable[struck: )] [inserted: period ]before marketing of a biosimilar biological product) that pertain to the marketing of such biosimilar biological product, or comparable documentation that is distributed to the shareholders of privately held companies.

(C) Aggregation rule

(i) In general All persons treated as a single employer under subsection (a) or (b) of section 52 of the Internal Revenue Code of 1986, or in a partnership, shall be treated as one manufacturer for purposes of paragraph (2)([struck: D][inserted: C])([struck: iv][inserted: iii]).

(ii) Partnership defined In clause (i), the term “partnership” means a syndicate, group, pool, joint venture, or other organization through or by means of which any business, financial operation, or venture is carried on by the manufacturer of the biological product and the manufacturer of the biosimilar biological product.

(2) Rules described The rules described in this paragraph are the following:

(A) Delayed selection and negotiation for [struck: 1][inserted: 2] [struck: year][inserted: years] If a determination of high likelihood is made under paragraph (3)[inserted: or paragraph (1)(B)(i) applies], the Secretary shall delay the inclusion of the biological product as a selected drug on the list published under subsection (a) until such list is published with respect to the initial price applicability year that is [struck: 1][inserted: 2] [struck: year][inserted: years] after the initial price applicability year for which the biological product would have been included as a selected drug on such list.

(B) If not licensed and marketed during the [struck: initial ]delay[inserted: .—] [inserted: If, during the time period between the selected drug publication date on which the biological product would have been included on the list as a selected drug pursuant to subsection (a) but for subparagraph (A), and the selected drug publication date with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list, the Secretary determines that such biological product is not the reference product for a biosimilar biological product that has been licensed and marketed under section 351(k) of the Public Health Service Act—]

(i) [struck: In general] [inserted: the Secretary shall include the biological product as a selected drug on the list published under subsection (a) with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for subparagraph (A); and]

[struck: If, during the time period between the selected drug publication date on which the biological product would have been included on the list as a selected drug pursuant to subsection (a) but for subparagraph (A) and the selected drug publication date with respect to the initial price applicability year that is 1 year after the initial price applicability year for which such biological product would have been included as a selected drug on such list, the Secretary determines that the biosimilar biological product for which the manufacturer submitted the request under paragraph (1)(B)(i)(II) (and for which the Secretary previously made a high likelihood determination under paragraph (3)) has not been licensed and marketed under section 262(k) of this title, the Secretary shall, at the request of such manufacturer—]

[struck: (I)] [struck: reevaluate whether there is a high likelihood (as described in paragraph (3)) that such biosimilar biological product will be licensed and marketed under such section 262(k) before the date that is 2 years after the selected drug publication date for which such biological product would have been included as a selected drug on such list published but for subparagraph (A); and]

[struck: (II)] [struck: evaluate whether, on the basis of clear and convincing evidence, the manufacturer of such biosimilar biological product has made a significant amount of progress (as determined by the Secretary) towards both such licensure and the marketing of such biosimilar biological product (based on information from items described in subclauses (I)(bb) and (II) of paragraph (1)(B)(ii)) since the receipt by the Secretary of the request made by such manufacturer under paragraph (1)(B)(i)(I).]

(ii) [struck: Selection and negotiation] [inserted: if such biosimilar biological product has not been licensed and marketed under section 351(k) of the Public Health Service Act on or before the date that is 2 years after the selected drug publication date on which the biological product would have been included on the list as a selected drug pursuant to subsection (a) but for subparagraph (A), the manufacturer of such biological product shall pay a rebate under paragraph (4) with respect to the years for which such manufacturer would have provided access to a maximum fair price for such biological product but for subparagraph (A).]

[struck: If the Secretary determines that there is not a high likelihood that such biosimilar biological product will be licensed and marketed as described in clause (i)(I) or there has not been a significant amount of progress as described in clause (i)(II)—]

[struck: (I)] [struck: the Secretary shall include the biological product as a selected drug on the list published under subsection (a) with respect to the initial price applicability year that is 1 year after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for subparagraph (A); and]

[struck: (II)] [struck: the manufacturer of such biological product shall pay a rebate under paragraph (4) with respect to the year for which such manufacturer would have provided access to a maximum fair price for such biological product but for subparagraph (A).]

[struck: (iii)] [struck: Second 1-year delay] [struck: If the Secretary determines that there is a high likelihood that such biosimilar biological product will be licensed and marketed (as described in clause (i)(I)) and a significant amount of progress has been made by the manufacturer of such biosimilar biological product towards such licensure and marketing (as described in clause (i)(II)), the Secretary shall delay the inclusion of the biological product as a selected drug on the list published under subsection (a) until the selected drug publication date of such list with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for this subsection.]

[struck: (C)] [struck: If not licensed and marketed during the year two delay] [struck: If, during the time period between the selected drug publication date of the list for which the biological product would have been included as a selected drug but for subparagraph (B)(iii) and the selected drug publication date with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list but for this subsection, the Secretary determines that such biosimilar biological product has not been licensed and marketed—]

[struck: (i)] [struck: the Secretary shall include such biological product as a selected drug on such list with respect to the initial price applicability year that is 2 years after the initial price applicability year for which such biological product would have been included as a selected drug on such list; and]

[struck: (ii)] [struck: the manufacturer of such biological product shall pay a rebate under paragraph (4) with respect to the years for which such manufacturer would have provided access to a maximum fair price for such biological product but for this subsection.]

[struck: (D)] [inserted: (C)] Limitations on delays

(i) Limited to 2 years In no case shall the Secretary delay the inclusion of a biological product on the list published under subsection (a) for more than 2 years.

[struck: (ii)] [struck: Exclusion of biological products that transitioned to a long-monopoly drug during the delay] [struck: In the case of a biological product for which the inclusion on the list published pursuant to subsection (a) was delayed by 1 year under subparagraph (A) and for which there would have been a change in status to a long-monopoly drug (as defined in section 1320f–3(c)(5) of this title) if such biological product had been a selected drug, in no case may the Secretary provide for a second 1-year delay under subparagraph (B)(iii).]

[struck: (iii)] [struck: Exclusion of biological products if more than 1 year since licensure] [struck: In no case shall the Secretary delay the inclusion of a biological product on the list published under subsection (a) if more than 1 year has elapsed since the biosimilar biological product has been licensed under section 262(k) of this title and marketing has not commenced for such biosimilar biological product.]

[struck: (iv)] [inserted: (ii)] Certain manufacturers of biosimilar biological products excluded In no case shall the Secretary delay the inclusion of a biological product as a selected drug on the list published under subsection (a) if Secretary determined that the manufacturer of the biosimilar biological product described in paragraph (1)(A)—

(I) is the same as the manufacturer of the reference product described in such paragraph or is treated as being the same pursuant to paragraph (1)(C); or

(II) has, based on information from items described in paragraph (1)(B)([struck: ii][inserted: iii])(I)(bb), entered into any agreement described in such paragraph with the manufacturer of the reference product described in paragraph (1)(A) that—

(aa) requires or incentivizes the manufacturer of the biosimilar biological product to submit a request described in paragraph (1)(B); or

(bb) restricts the quantity (either directly or indirectly) of the biosimilar biological product that may be sold in the United States over a specified period of time.

(3) High likelihood[inserted: .—] [struck: For purposes of this subsection, there is a high likelihood described in paragraph (1) or paragraph (2), as applicable, if the Secretary finds that—]

(A) [inserted: In general.—] [struck: an][inserted: Subject] [struck: application][inserted: to] [inserted: subparagraph (B), ]for [struck: licensure][inserted: purposes] [struck: under][inserted: of] [struck: section][inserted: this] [struck: 262][inserted: subsection, there is a high likelihood described in paragraph ]([struck: k][inserted: 1]) [struck: of][inserted: or] [struck: this][inserted: paragraph] [struck: title][inserted: (2),] [struck: for][inserted: as] [inserted: applicable, if ]the [struck: biosimilar][inserted: Secretary] [struck: biological][inserted: determines] [struck: product][inserted: that] [struck: has][inserted: information] [struck: been][inserted: submitted] [struck: accepted][inserted: to] [struck: for][inserted: the] [struck: review][inserted: Secretary] [inserted: by any person ]or [struck: approved][inserted: obtained] by the [struck: Food][inserted: Secretary] [struck: and][inserted: from] [struck: Drug][inserted: any] [struck: Administration;][inserted: other] [inserted: source provides clear ]and[inserted: convincing evidence that such biosimilar biological product will, within the time period specified under paragraph (1)(A) be marketed.]

(B) [inserted: Determination requirements.—] [struck: information][inserted: Before] [struck: from][inserted: determining] [struck: items][inserted: whether] [struck: described][inserted: there] [struck: in][inserted: is] [struck: sub][inserted: a] [struck: clauses][inserted: high] [struck: (I)(bb)][inserted: likelihood] [struck: and][inserted: described] [struck: (III)][inserted: in] [struck: of ]paragraph (1)[struck: (B)(ii)] [struck: submitted][inserted: or] [struck: to][inserted: paragraph] [inserted: (2), ]the Secretary [struck: by][inserted: shall] [inserted: inform ]the manufacturer [struck: requesting][inserted: of] [struck: a][inserted: the] [struck: delay][inserted: biosimilar] [struck: under][inserted: biological] [struck: such][inserted: product] [struck: paragraph][inserted: of] [struck: provides][inserted: the] [struck: clear][inserted: information] [inserted: on which the Secretary intends to rely in making such determination ]and [struck: convincing][inserted: shall] [struck: evidence][inserted: require] that such [struck: biosimilar][inserted: manufacturer] [struck: biological][inserted: confirms] [struck: product][inserted: in] [struck: will][inserted: writing], [struck: within][inserted: under] [struck: the][inserted: penalty] [struck: time][inserted: of] [struck: period][inserted: perjury,] [struck: specified][inserted: the] [struck: under][inserted: accuracy] [struck: paragraph][inserted: of] [struck: (1)(A)][inserted: such] [inserted: information ]or [struck: (2)(B)(i)(I),][inserted: correct] [struck: be][inserted: any] [struck: marketed][inserted: such inaccurate information].

(C) [inserted: Clarification.—] [inserted: The existence of pending or prospective patent litigation regarding the biosimilar biological product shall not preclude a finding of high likelihood under this paragraph.]

(4) Rebate

(A) In general For purposes of [struck: subparagraphs][inserted: paragraph] ([struck: B][inserted: 2])([struck: ii][inserted: B])([struck: II) and (C)(]ii)[struck: of paragraph (2)], in the case of a biological product for which the inclusion on the list under subsection (a) was delayed under this subsection and for which the Secretary has negotiated and entered into an agreement under section 1320f–2 of this title with respect to such biological product, the manufacturer shall be required to pay a rebate to the Secretary at such time and in such manner as determined by the Secretary.

(B) Amount Subject to subparagraph (C), the amount of the rebate under subparagraph (A) with respect to a biological product shall be equal to the estimated amount—

(i) in the case of a biological product that is a covered part D drug (as defined in section 1395w–102(e) of this title), that is the sum of the products of—

(I) 75 percent of the amount by which[inserted: the average manufacturer price, as reported by the manufacturer of such covered part D drug under section 1927 (or, if not reported by such manufacturer under section 1927, as reported by such manufacturer to the Secretary pursuant to the agreement under section 1193(a)) for such biological product, with respect to each of the calendar quarters of the price applicability period that would have applied but for this subsection; exceeds]—

(aa) [inserted: for ]the [struck: average][inserted: initial] [struck: manufacturer ]price[struck: ,] [struck: as][inserted: applicability] [struck: reported][inserted: year] [struck: by][inserted: that] [struck: the][inserted: would] [struck: manufacturer][inserted: have] [struck: of][inserted: applied] [struck: such][inserted: but] [struck: covered][inserted: for] [struck: part][inserted: a] [struck: D][inserted: delay] [struck: drug ]under [struck: section][inserted: paragraph] [struck: 1396r–8 of this title ]([struck: or][inserted: 2)(A)], [struck: if not reported by such manufacturer under section 1396r–8 of this title, as reported by such manufacturer to ]the [struck: Secretary][inserted: maximum] [struck: pursuant][inserted: fair] [struck: to][inserted: price] [struck: the][inserted: negotiated] [struck: agreement ]under section [struck: 1320f–2(a)][inserted: 1194] [struck: of this title) ]for such biological product[struck: ,] [struck: with][inserted: under] [struck: respect][inserted: such] [struck: to each of the calendar quarters of the price applicability period that would have applied but for this subsection][inserted: agreement]; [struck: exceeds][inserted: or]

(bb) [inserted: for the second year of such delay, such maximum fair price, increased as described in section 1195(b)(1)(A); and]

[struck: in the initial price applicability year that would have applied but for a delay under—]

[struck: (AA)] [struck: paragraph (2)(A), the maximum fair price negotiated under section 1320f–3 of this title for such biological product under such agreement; or]

[struck: (BB)] [struck: paragraph (2)(B)(iii), such maximum fair price, increased as described in section 1320f–4(b)(1)(A) of this title; and]

(II) the number of units dispensed under part D of subchapter XVIII for such covered part D drug during each such calendar quarter of such price applicability period; and

(ii) in the case of a biological product for which payment may be made under part B of subchapter XVIII, that is the sum of the products of—

(I) 80 percent of the amount by which[inserted: the payment amount for such biological product under section 1847A(b), with respect to each of the calendar quarters of the price applicability period that would have applied but for this subsection; exceeds]—

(aa) [inserted: for ]the [struck: payment][inserted: initial] [struck: amount][inserted: price] [struck: for][inserted: applicability] [struck: such][inserted: year] [struck: biological][inserted: that] [struck: product][inserted: would] [struck: under][inserted: have] [struck: section][inserted: applied] [struck: 1395w–3a(b)][inserted: but] [struck: of][inserted: for] [struck: this][inserted: a] [struck: title,][inserted: delay] [struck: with][inserted: under] [struck: respect][inserted: paragraph] [struck: to][inserted: (2)(A),] [struck: each of ]the [struck: calendar][inserted: maximum] [struck: quarters][inserted: fair] [struck: of the ]price [struck: applicability][inserted: negotiated] [struck: period][inserted: under] [struck: that][inserted: section] [struck: would][inserted: 1194] [struck: have][inserted: for] [struck: applied][inserted: such] [struck: but][inserted: biological] [struck: for][inserted: product] [struck: this][inserted: under] [struck: subsection][inserted: such agreement]; [struck: exceeds][inserted: or]

(bb) [inserted: for the second year of such delay, such maximum fair price, increased as described in section 1195(b)(1)(A); and]

[struck: in the initial price applicability year that would have applied but for a delay under—]

[struck: (AA)] [struck: paragraph (2)(A), the maximum fair price negotiated under section 1320f–3 of this title for such biological product under such agreement; or]

[struck: (BB)] [struck: paragraph (2)(B)(iii), such maximum fair price, increased as described in section 1320f–4(b)(1)(A) of this title; and]

(II) the number of units (excluding units that are packaged into the payment amount for an item or service and are not separately payable under such part B) of the billing and payment code of such biological product administered or furnished under such part B during each such calendar quarter of such price applicability period.

(C) Special rule for delayed biological products that are long-monopoly drugs

§ 1320f–1(f)–(g)

(f)(4)(C)(i)–(D)(i) unchanged ·

(ii) in the case such biological product is a covered part D drug (as defined in section 1395w–102(e) of this title), the Medicare Prescription Drug Account under section 1395w–116 of this title in such Trust Fund.

(5) Definitions of biosimilar biological product In this subsection, the term “biosimilar biological product” has the meaning given such term in section 1395w–3a(c)(6) of this title.

(g) [inserted: Definition of marketed.—] [inserted: In this section, the term “marketed” means, with respect to a drug or biological product (including a biosimilar biological product) introduced or delivered for introduction into interstate commerce.]

Step through the changes